title: Failure of intravitreal bevacizumab in the treatment of choroidal metastasis.
abstract: BACKGROUND
  Metastasis to choroid is the most common intraocular malignancy, arising most frequently from carcinoma of breast in women and lung in men. Recent case reports have described successful use of intravitreal bevacizumab to achieve local control of such tumours.
  
  
  METHODS
  Five cases of choroidal metastases from varying primaries: breast, lung, and colon were treated with intravitreal bevacizumab, and tumour response observed and documented with serial photographs and B-scans.
  
  
  RESULTS
  Four of the five tumours were seen to progress despite intravitreal bevacizumab treatment.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab as the primary treatment of choroidal metastases is not recommended and should not delay more effective alternative treatments.
authors.affiliation: Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, UK.
authors.forename: A
authors.initials: A
authors.lastname: Maudgil
authors.affiliation: Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, UK.
authors.forename: K S
authors.initials: KS
authors.lastname: Sears
authors.affiliation: Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, UK.
authors.forename: P A
authors.initials: PA
authors.lastname: Rundle
authors.affiliation: Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, UK.
authors.forename: I G
authors.initials: IG
authors.lastname: Rennie
authors.affiliation: Sheffield Ocular Oncology Service, Department of Ophthalmology, Royal Hallamshire Hospital, Sheffield, UK.
authors.forename: S M
authors.initials: SM
authors.lastname: Salvi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary; D002432:Cecum; D002830:Choroid Neoplasms / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007414:Intestinal Neoplasms / Q000473:pathology*; D058449:Intravitreal Injections; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D041623:Tomography, Optical Coherence; D017211:Treatment Failure; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab